Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Sep;36(3):229–235. doi: 10.1111/j.1365-2125.1993.tb04222.x

Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients.

B C Israel 1, R A Blouin 1, W McIntyre 1, S I Shedlofsky 1
PMCID: PMC1364643  PMID: 9114909

Abstract

1. The influence of interferon-alpha (IFN alpha) on the clearances of theophylline (TH), antipyrine (AP) and hexobarbitone (HB) was studied in seven cancer patients given IFN alpha as their only treatment. In addition, IFN alpha effects on drug clearance were correlated with changes in serum inflammatory cytokines and acute phase proteins. 2. A 'baseline' study was performed by administering an oral drug 'cocktail' of TH (150 mg), AP (250 mg) and HB (250 mg) with saline injected simultaneously and again 24 h later. One week later, an 'acute' study was performed at the initiation of IFN alpha therapy, 3 x 10(6) units injected with the drug cocktail and again 24 h later. After 2 weeks of IFN alpha treatment three times per week, a 'chronic' study was performed with IFN alpha injected the day prior to, simultaneously with, as well as 24 h after the drug cocktail. 3. Plasma samples were collected over 48 h and the clearances of TH, AP and HB were estimated. Serum samples were collected at various times for the measurement of tumor necrosis factor (TNF), interleukin-1 (IL-1), interleukin-6 (IL-6), C-reactive protein (C-RP) and alpha 1-acid glycoprotein (AGP). 4. IFN alpha caused a 33% decrease in the oral clearance of TH during the chronic study compared with baseline (P < or = 0.05). Although IFN alpha inhibited TH clearance by 16% during the acute study and AP clearance by 20-21% during both acute and chronic studies, these changes did not reach statistical significance. IFN alpha caused minimal changes in HB clearance. There were no chronic effects of IFN alpha on serum cytokines or acute phase proteins. 5. The findings confirm that the most commonly used dose of IFN alpha inhibits the hepatic clearance in humans of some but not all drugs and that this inhibition persists during IFN alpha therapy. Because inhibition was not associated with increases in serum cytokines or acute phase proteins, the mechanism by which IFN alpha inhibits cytochrome P450 activities in vivo does not appear to involve inflammatory mediators such as TNF. IL-1 or IL-6.

Full text

PDF
229

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarden L. A., De Groot E. R., Schaap O. L., Lansdorp P. M. Production of hybridoma growth factor by human monocytes. Eur J Immunol. 1987 Oct;17(10):1411–1416. doi: 10.1002/eji.1830171004. [DOI] [PubMed] [Google Scholar]
  2. Berthou F., Ratanasavanh D., Alix D., Carlhant D., Riche C., Guillouzo A. Caffeine and theophylline metabolism in newborn and adult human hepatocytes; comparison with adult rat hepatocytes. Biochem Pharmacol. 1988 Oct 1;37(19):3691–3700. doi: 10.1016/0006-2952(88)90402-9. [DOI] [PubMed] [Google Scholar]
  3. Bertini R., Bianchi M., Villa P., Ghezzi P. Depression of liver drug metabolism and increase in plasma fibrinogen by interleukin 1 and tumor necrosis factor: a comparison with lymphotoxin and interferon. Int J Immunopharmacol. 1988;10(5):525–530. doi: 10.1016/0192-0561(88)90069-0. [DOI] [PubMed] [Google Scholar]
  4. Brian W. R., Srivastava P. K., Umbenhauer D. R., Lloyd R. S., Guengerich F. P. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry. 1989 Jun 13;28(12):4993–4999. doi: 10.1021/bi00438a014. [DOI] [PubMed] [Google Scholar]
  5. Brouwer K. L., Kostenbauder H. B., McNamara P. J., Blouin R. A. Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration. J Pharmacol Exp Ther. 1984 Dec;231(3):649–653. [PubMed] [Google Scholar]
  6. Campbell M. E., Grant D. M., Inaba T., Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos. 1987 Mar-Apr;15(2):237–249. [PubMed] [Google Scholar]
  7. Candler R. V., Rouse B. T., Moore R. N. Regulation of interleukin 1 production by alpha and beta interferons: evidence for both direct and indirect enhancement. J Interferon Res. 1985 Winter;5(1):179–189. doi: 10.1089/jir.1985.5.179. [DOI] [PubMed] [Google Scholar]
  8. Chang S. L., Emmick K., Wedlund P. J. Characterization of antipyrine autoinduction in the rat utilizing a new microsampling technique for serial blood sample collections. J Pharm Sci. 1986 May;75(5):456–458. doi: 10.1002/jps.2600750507. [DOI] [PubMed] [Google Scholar]
  9. Craig P. I., Mehta I., Murray M., McDonald D., Aström A., van der Meide P. H., Farrell G. C. Interferon down regulates the male-specific cytochrome P450IIIA2 in rat liver. Mol Pharmacol. 1990 Sep;38(3):313–318. [PubMed] [Google Scholar]
  10. Craig P. I., Tapner M., Farrell G. C. Interferon suppresses erythromycin metabolism in rats and human subjects. Hepatology. 1993 Feb;17(2):230–235. [PubMed] [Google Scholar]
  11. Craig P. I., Williams S. J., Cantrill E., Farrell G. C. Rat but not human interferons suppress hepatic oxidative drug metabolism in rats. Gastroenterology. 1989 Oct;97(4):999–1004. doi: 10.1016/0016-5085(89)91509-6. [DOI] [PubMed] [Google Scholar]
  12. Elin R. J., Vesell E. S., Wolff S. M. Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance. Clin Pharmacol Ther. 1975 Apr;17(4):447–457. doi: 10.1002/cpt1975174447. [DOI] [PubMed] [Google Scholar]
  13. Franklin M. R., Finkle B. S. Effect of murine gamma-interferon on the mouse liver and its drug-metabolizing enzymes: comparison with human hybrid alpha-interferon. J Interferon Res. 1985 Spring;5(2):265–272. doi: 10.1089/jir.1985.5.265. [DOI] [PubMed] [Google Scholar]
  14. Fuhr U., Doehmer J., Battula N., Wölfel C., Kudla C., Keita Y., Staib A. H. Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem Pharmacol. 1992 Jan 22;43(2):225–235. doi: 10.1016/0006-2952(92)90282-n. [DOI] [PubMed] [Google Scholar]
  15. Ghezzi P., Bianchi M., Mantovani A., Spreafico F., Salmona M. Enhanced xanthine oxidase activity in mice treated with interferon and interferon inducers. Biochem Biophys Res Commun. 1984 Feb 29;119(1):144–149. doi: 10.1016/0006-291x(84)91630-9. [DOI] [PubMed] [Google Scholar]
  16. Ghezzi P., Saccardo B., Bianchi M. Recombinant tumor necrosis factor depresses cytochrome P450-dependent microsomal drug metabolism in mice. Biochem Biophys Res Commun. 1986 Apr 14;136(1):316–321. doi: 10.1016/0006-291x(86)90912-5. [DOI] [PubMed] [Google Scholar]
  17. Ghezzi P., Saccardo B., Villa P., Rossi V., Bianchi M., Dinarello C. A. Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infect Immun. 1986 Dec;54(3):837–840. doi: 10.1128/iai.54.3.837-840.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Grygiel J. J., Miners J. O., Drew R., Birkett D. J. Differential effects of cimetidine on theophylline metabolic pathways. Eur J Clin Pharmacol. 1984;26(3):335–340. doi: 10.1007/BF00548764. [DOI] [PubMed] [Google Scholar]
  19. Hill D. B., Marsano L., Cohen D., Allen J., Shedlofsky S., McClain C. J. Increased plasma interleukin-6 concentrations in alcoholic hepatitis. J Lab Clin Med. 1992 May;119(5):547–552. [PubMed] [Google Scholar]
  20. Jonkman J. H., Nicholson K. G., Farrow P. R., Eckert M., Grasmeijer G., Oosterhuis B., De Noord O. E., Guentert T. W. Effects of alpha-interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharmacol. 1989 Jun;27(6):795–802. doi: 10.1111/j.1365-2125.1989.tb03442.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Knickle L. C., Spencer D. F., Renton K. W. The suppression of hepatic cytochrome P4504A mRNA mediated by the interferon inducer polyinosinic acid.polycytidylic acid. Biochem Pharmacol. 1992 Aug 4;44(3):604–608. doi: 10.1016/0006-2952(92)90458-u. [DOI] [PubMed] [Google Scholar]
  22. Knodell R. G., Dubey R. K., Wilkinson G. R., Guengerich F. P. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther. 1988 Jun;245(3):845–849. [PubMed] [Google Scholar]
  23. Kramer S. M., Carver M. E. Serum-free in vitro bioassay for the detection of tumor necrosis factor. J Immunol Methods. 1986 Nov 6;93(2):201–206. doi: 10.1016/0022-1759(86)90189-4. [DOI] [PubMed] [Google Scholar]
  24. Loft S. Metronidazole and antipyrine as probes for the study of foreign compound metabolism. Pharmacol Toxicol. 1990;66 (Suppl 6):1–31. doi: 10.1111/j.1600-0773.1990.tb01611.x. [DOI] [PubMed] [Google Scholar]
  25. Mannering G. J., Deloria L. B. The pharmacology and toxicology of the interferons: an overview. Annu Rev Pharmacol Toxicol. 1986;26:455–515. doi: 10.1146/annurev.pa.26.040186.002323. [DOI] [PubMed] [Google Scholar]
  26. Mannering G. J., Renton K. W., el Azhary R., Deloria L. B. Effects of interferon-inducing agents on hepatic cytochrome P-450 drug metabolizing systems. Ann N Y Acad Sci. 1980;350:314–331. doi: 10.1111/j.1749-6632.1980.tb20631.x. [DOI] [PubMed] [Google Scholar]
  27. Moochhala S. M., Renton K. W. A role for xanthine oxidase in the loss of cytochrome P-450 evoked by interferon. Can J Physiol Pharmacol. 1991 Jul;69(7):944–950. doi: 10.1139/y91-143. [DOI] [PubMed] [Google Scholar]
  28. Moochhala S. M., Renton K. W., Stebbing N. Induction and depression of cytochrome P-450-dependent mixed-function oxidase by a cloned consensus alpha-interferon (IFN-alpha CON1) in the hamster. Biochem Pharmacol. 1989 Feb 1;38(3):439–447. doi: 10.1016/0006-2952(89)90383-3. [DOI] [PubMed] [Google Scholar]
  29. Morgan E. T. Suppression of P450IIC12 gene expression and elevation of actin messenger ribonucleic acid levels in the livers of female rats after injection of the interferon inducer poly rI.poly rC. Biochem Pharmacol. 1991 Jun 21;42(1):51–57. doi: 10.1016/0006-2952(91)90680-4. [DOI] [PubMed] [Google Scholar]
  30. Okuno H., Takasu M., Kano H., Seki T., Shiozaki Y., Inoue K. Depression of drug-metabolizing activity in the human liver by interferon-beta. Hepatology. 1993 Jan;17(1):65–69. [PubMed] [Google Scholar]
  31. Park B. K., Kitteringham N. R. Assessment of enzyme induction and enzyme inhibition in humans: toxicological implications. Xenobiotica. 1990 Nov;20(11):1171–1185. doi: 10.3109/00498259009046837. [DOI] [PubMed] [Google Scholar]
  32. Parkinson A., Lasker J., Kramer M. J., Huang M. T., Thomas P. E., Ryan D. E., Reik L. M., Norman R. L., Levin W., Conney A. H. Effects of three recombinant human leukocyte interferons on drug metabolism in mice. Drug Metab Dispos. 1982 Nov-Dec;10(6):579–585. [PubMed] [Google Scholar]
  33. Renton K. W., Mannering G. J. Depression of hepatic cytochrome P-450-dependent monooxygenase systems with administered interferon inducing agents. Biochem Biophys Res Commun. 1976 Nov 22;73(2):343–348. doi: 10.1016/0006-291x(76)90713-0. [DOI] [PubMed] [Google Scholar]
  34. Robson R. A., Miners J. O., Matthews A. P., Stupans I., Meller D., McManus M. E., Birkett D. J. Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies. Biochem Pharmacol. 1988 May 1;37(9):1651–1659. doi: 10.1016/0006-2952(88)90423-6. [DOI] [PubMed] [Google Scholar]
  35. Sarkar M. A., Hunt C., Guzelian P. S., Karnes H. T. Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos. 1992 Jan-Feb;20(1):31–37. [PubMed] [Google Scholar]
  36. Sarkar M., Polk R. E., Guzelian P. S., Hunt C., Karnes H. T. In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes. Antimicrob Agents Chemother. 1990 Apr;34(4):594–599. doi: 10.1128/aac.34.4.594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Schellens J. H., Janssens A. R., van der Wart J. H., van der Velde E. A., Breimer D. D. Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a 'cocktail' approach. Eur J Clin Invest. 1989 Oct;19(5):472–479. doi: 10.1111/j.1365-2362.1989.tb00262.x. [DOI] [PubMed] [Google Scholar]
  38. Schellens J. H., van der Wart J. H., Danhof M., van der Velde E. A., Breimer D. D. Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach. Br J Clin Pharmacol. 1988 Oct;26(4):373–384. doi: 10.1111/j.1365-2125.1988.tb03394.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Shedlofsky S. I., Swim A. T., Robinson J. M., Gallicchio V. S., Cohen D. A., McClain C. J. Interleukin-1 (IL-1) depresses cytochrome P450 levels and activities in mice. Life Sci. 1987 Jun 15;40(24):2331–2336. doi: 10.1016/0024-3205(87)90506-6. [DOI] [PubMed] [Google Scholar]
  40. Singh G., Renton K. W., Stebbing N. Homogeneous interferon from E. coli depresses hepatic cytochrome P-450 and drug biotransformation. Biochem Biophys Res Commun. 1982 Jun 30;106(4):1256–1261. doi: 10.1016/0006-291x(82)91247-5. [DOI] [PubMed] [Google Scholar]
  41. Stanley L. A., Adams D. J., Balkwill F. R., Griffin D., Wolf C. R. Differential effects of recombinant interferon alpha on constitutive and inducible cytochrome P450 isozymes in mouse liver. Biochem Pharmacol. 1991 Jul 5;42(2):311–320. doi: 10.1016/0006-2952(91)90718-k. [DOI] [PubMed] [Google Scholar]
  42. Teunissen M. W., Meerburg-van der Torren J. E., Vermeulen N. P., Breimer D. D. Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine. J Chromatogr. 1983 Dec 9;278(2):367–378. [PubMed] [Google Scholar]
  43. Williams S. J., Baird-Lambert J. A., Farrell G. C. Inhibition of theophylline metabolism by interferon. Lancet. 1987 Oct 24;2(8565):939–941. doi: 10.1016/s0140-6736(87)91422-x. [DOI] [PubMed] [Google Scholar]
  44. Williams S. J., Farrell G. C. Inhibition of antipyrine metabolism by interferon. Br J Clin Pharmacol. 1986 Nov;22(5):610–612. doi: 10.1111/j.1365-2125.1986.tb02943.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Wright K., Morgan E. T. Regulation of cytochrome P450IIC12 expression by interleukin-1 alpha, interleukin-6, and dexamethasone. Mol Pharmacol. 1991 Apr;39(4):468–474. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES